<DOC>
	<DOCNO>NCT00119340</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy , fludarabine , radiation therapy donor stem cell transplant help stop growth cancer cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase I/II trial study side effect best dose fludarabine , total-body irradiation , donor stem cell transplant follow cyclosporine mycophenolate mofetil see well work treat patient chronic myelogenous leukemia .</brief_summary>
	<brief_title>Fludarabine , Total-Body Irradiation , Donor Stem Cell Transplant Followed By Cyclosporine Mycophenolate Mofetil Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether increase intensity nonmyeloablative conditioning regimen comprise fludarabine total body irradiation allow achievement donor T-cell chimerism level &gt; 40 % day 28 post-transplantation 90 % patient chronic myelogenous leukemia undergo allogeneic peripheral blood stem cell transplantation immunosuppression comprise cyclosporine mycophenolate mofetil . - Determine feasibility reduce day 84 graft rejection rate/graft failure &lt; 10 % patient treated regimen . - Determine feasibility maintain incidence grade 4 acute graft-versus-host disease &lt; 10 % patient treated regimen . - Determine feasibility maintain day 200 nonrelapse mortality rate &lt; 15 % patient treated regimen . Secondary - Determine rate complete cytogenetic remission patient treat regimen . - Determine probability actuarial disease-free survival patient treat regimen . - Determine pharmacokinetics mycophenolate mofetil fludarabine patient . OUTLINE : This multicenter , dose-escalation study fludarabine total-body irradiation ( TBI ) . - Nonmyeloablative conditioning regimen : Patients receive fludarabine IV day -4 -2 OR day -6 -2 . Patients undergo TBI day 0 . - Allogeneic peripheral blood stem cell transplantation ( PBSCT ) : After completion TBI , patient undergo allogeneic PBSCT day 0 . - Immunosuppression : Patients receive oral cyclosporine twice daily day -3 100 followed taper day 177 absence graft-versus-host disease ( GVHD ) . Beginning within 4-6 hour completion PBSCT , patient receive oral mycophenolate mofetil 2-3 time daily day 0-40 followed taper day 96 absence GVHD . Cohorts 5-25 patient receive cumulative dos fludarabine escalate dos TBI 2 5 , 3 10-15 , 4 20 , 5 25 patient experience day 28 post-transplant T-cell chimerism level ≤ 40 % and/or day 84 post-transplant graft rejection rate &gt; 10 % . After completion study transplantation , patient follow 3 time weekly 3 month , 6 , 12 , 18 month , annually 5 year , periodically thereafter . PROJECTED ACCRUAL : A total 5-75 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic myelogenous leukemia ( CML ) , meet 1 follow criterion : First second chronic phase Philadelphia chromosomepositive ( Ph+ ) disease cytogenetics fluorescent situ hybridization ( FISH ) First accelerate phase , meet follow criterion : More 10 % &lt; 30 % myeloblast promyelocytes bone marrow peripheral blood Any additional clonal cytogenetic abnormality Increasing splenomegally Extramedullary tumor WBC , platelet count , hematocrit pertubations control therapy hydroxyurea , interferon , imatininb mesylate Persistent unexplained fever bone pain Less 5 % blast marrow time transplant No blast crisis No curative therapy exist Received prior imatinib mesylate AND meet ≥ 1 follow criterion : Hematologic evidence disease progression Lack complete hematologic response 3 month treatment imatinib mesylate Cytogenetic evidence disease progression , define increase Ph+ cell BCR/ABLpositive ( BCR/ABL+ ) cell &gt; 25 % Lack complete cytogenetic remission ( Ph+ cell cytogenetic analysis BCR/ABL+ cell FISH ) 1 year treatment imatinib mesylate At least 65 % Ph+ cell cytogenetic analysis BCR/ABL+ cell FISH 6 month treatment imatinib mesylate Less 3log reduction BCR/ABL mRNA level quantitative polymerase chain reaction ( QPCR ) compare standard baseline level 1 year treatment imatinib mesylate Molecular evidence disease progression , define &gt; 1 log increase BCR/ABL mRNA level QPCR , detect 2 sample Experienced adverse event imatinib mesylate treatment would preclude administration drug Patient refuse treatment imatinib mesylate despite lack disease progression Refused conventional myeloablative allogeneic stem cell transplantation OR high risk regimenrelated toxicity due preexist medical condition ( patient &lt; 50 year age ) Unrelated donor available Matched HLAA , B , C , DRB1 , DQB1 highresolution type A single allele* disparity HLAA , B , C allow Negative antidonor cytotoxic crossmatch Not marrow donor NOTE : *Patient donor pair homozygous mismatch allele ( e.g. , patient A*0101 donor A*0201 ) consider twoallele mismatch allow No CNS involvement disease refractory intrathecal chemotherapy PATIENT CHARACTERISTICS : Age Any age Performance status Karnofsky 70100 % Lanksy 50100 % ( pediatric patient ) Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic No fulminant liver failure No cirrhosis liver evidence portal hypertension No alcoholic hepatitis No esophageal varices No history bleed esophageal varix No hepatic encephalopathy No uncorrectable hepatic synthetic dysfunction evidence prolongation PT No ascites relate portal hypertension No bacterial fungal liver abscess No biliary obstruction No chronic viral hepatitis AND bilirubin &gt; 3 mg/dL No symptomatic biliary disease Renal Not specify Cardiovascular Ejection fraction ≥ 40 % No cardiac failure require therapy No poorly control hypertension ( i.e. , blood pressure ≥ 150/90 mm Hg despite standard medication ) Pulmonary DLCO ≥ 35 % ( correct ) No requirement supplementary continuous oxygen Pulmonary nodule allow discretion principal investigator Immunologic HIV negative No uncontrolled systemic infection No fungal infection radiological progression treatment amphotericin B active triazole &gt; 1 month Other Not pregnant nursing Fertile patient must use effective contraception 12 month completion study treatment No active malignancy except nonmelanoma skin cancer No prior localize malignancy high risk ( ≥ 20 % ) recurrence PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics See Chemotherapy Chemotherapy See Disease Characteristics More 3 week since prior cytotoxic chemotherapy Imatinib mesylate interferon consider cytotoxic chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
</DOC>